Loading...
Loading...
All product recalls affecting Kentucky.
Includes nationwide recalls (tagged “Nationwide”) and recalls with Kentucky in the distribution area.
may contain metal pieces
may contain metal pieces
may contain metal pieces
may contain metal pieces
may contain metal pieces
may contain metal pieces
may contain metal pieces
may contain metal pieces
Jaguar Land Rover North America, LLC (Land Rover) is recalling certain 2020-2025 Land Rover Defender vehicles equipped with Raised Air Intake (RAI) aftermarket accessory equipment, with part number VPLEP0543. The raised air intake may not be secured properly, which can allow the intake to detach from the vehicle.
Forest River, Inc (Forest River) is recalling certain 2024-2025 Clipper and Viking travel trailers. Please see the recall report for a complete list of models. The bottle bracket welds may break and cause the propane tank to detach from the vehicle.
Forest River, Inc. (Forest River) is recalling certain 2009-2017 Georgetown Class A motorhomes. The amber turn signal lens has an undersized reflective surface. As such, these vehicles fail to comply with the requirements of Federal Motor Vehicle Safety Standard (FMVSS) number 108, "Lamps, Reflective Devices, and Associated Equipment."
There is a software issue that can result in the loss of patient monitoring on the Portrait Central Viewer Application after 425 days of continuous run-time.
McNeilus Truck & Manufacturing, Inc. (McNeilus) is recalling certain 2024 Atlantic and Zero Radius Side Loader vehicles equipped with certain Agility Fuel Solutions CNG Fuel Systems, using part number 10300466. The manual cylinder valves may develop stress corrosion cracks in the bottom plugged port, causing a leak.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.
CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.